Clinical presentation of bone metastases in neuroendocrine tumors: a retrospective cohort study
Endocrine-Related Cancer · 2025
DOI: 10.1530/erc-25-0147 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Endocrine-Related Cancer, 2025. Verfasst von Elisabetta Lavezzi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology, Diabetology and Medical Andrology Unit, IRCCS, Humanitas Research Hospital, Rozzano, Milan, Italy. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Bone Neoplasms, Pancreatic Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
Bone metastases (BMs) are a rare and late event in patients with neuroendocrine tumors (NETs). The aim of our study was to investigate the clinical presentation and outcome of BMs in a large cohort of patients with NETs. A retrospective study was performed at two referral centers of Northern Italy (IRCCS Humanitas Research Hospital in Milan and Santa Maria della Misericordia University Hospital in Udine). Three hundred fifty-two consecutive patients with either gastroenteropancreatic or non-gastroenteropancreatic NETs were included: 52 patients with synchronous or metachronous BMs (BM-positive) and 300 patients with metastatic disease without BMs (BM-negative). Patients with BMs showed a higher prevalence of smoking habit (41.2 vs 21.8%, P = 0.004) and carcinoid syndrome (28.8 vs 5.7%, P <0.001) compared to patients without BMs. In addition, higher levels of chromogranin A (P = 0.001), urinary 5-hydroxyindoleacetic acid (P <0.001), parathyroid hormone (P = 0.022), and alkaline phosphatase (P = 0.018) were found compared to the BM-negative group. Patients with BMs had more frequently a primary lung NET compared to the BM-negative group (19.2 vs 0.7%, P = 0.001) and grade G2 or G3 gastroenteropancreatic tumors (P <0.001) compared to the BM-negative group. During a median follow-up of 4.2 years, a higher mortality rate was registered in the BM-positive group as compared to BM-negative group (42.3 vs 4.0%, P = 0.001). BMs were more common in patients with lung NETs, G2–G3 grade tumors, and in those with carcinoid syndrome. BMs affected patients’ prognosis, highlighting the importance of investigating and managing this condition in patients with NETs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Endocrinology, Diabetology and Medical Andrology Unit, IRCCS, Humanitas Research Hospital, Rozzano, Milan, Italy.
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
- Endocrinology Unit, University Hospital Santa Maria della Misericordia, Udine, Italy.
- Biostatistics Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
- Gastroenterology Department, IRCCS, Humanitas Research Hospital, Rozzano, Milan, Italy.
- Pathology Department, IRCCS, Humanitas Research Hospital, Rozzano, Milan, Italy.
ORCID-Profile: Gherardo Mazziotti
Zitieren
APA
Lavezzi, E., Jaafar, S., Chiardi, I., Brunetti, A., Morenghi, E., Rossi, R. E., Cellini, M., Birtolo, M. F., Uccella, S., Zerbi, A., Laffi, A., Bertuzzi, A., Vescini, F., Mazziotti, G., & Lania, A. G. A. (2025). Clinical presentation of bone metastases in neuroendocrine tumors: a retrospective cohort study. Endocrine-Related Cancer. https://doi.org/10.1530/erc-25-0147
Vancouver
Lavezzi E, Jaafar S, Chiardi I, Brunetti A, Morenghi E, Rossi RE, et al. Clinical presentation of bone metastases in neuroendocrine tumors: a retrospective cohort study. Endocrine-Related Cancer. 2025. doi:10.1530/erc-25-0147
BibTeX
@article{Lavezzi2025,
author = {Lavezzi, Elisabetta and Jaafar, Simona and Chiardi, Isabella and Brunetti, Alessandro and Morenghi, Emanuela and Rossi, Roberta Elisa and Cellini, Miriam and Birtolo, Maria Francesca and Uccella, Silvia and Zerbi, Alessandro and Laffi, Alice and Bertuzzi, Alexia and Vescini, Fabio and Mazziotti, Gherardo and Lania, Andrea Gerardo Antonio},
title = {Clinical presentation of bone metastases in neuroendocrine tumors: a retrospective cohort study},
journal = {Endocrine-Related Cancer},
year = {2025},
doi = {10.1530/erc-25-0147}
}
EUVIMED